81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results

https://doi.org/10.1016/j.annonc.2022.02.091Get rights and content
Under an Elsevier user license
open archive

Cited by (0)